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Background & Aims: Cachexia is frequent in advanced cancer and is 
associated with adverse outcomes; however, definite diagnostic criteria for 
cachexia are not established. Diet energy density (ED) may affect energy 
intake (EI) and energy balance. Patient characteristics may also influence 
such associations. This potentially hampers cachexia treatment and dietary 
treatment in clinical practice. 
The aim was to study associations between ED and EI in palliative cancer 
patients and whether ED or EI predict energy balance, and the influence of 
systemic inflammation and survival time. The prevalence of reduced quality 
of life (QoL), function and survival, in patients classified by different 
cachexia criteria were compared. 
Methods: Dietary intake and ED was assessed by food records (n=251-322). 
Energy balance was calculated from the change in body energy content by 
repeated DXA scans in 107 patients for a total of 164 4-month periods. 
Linear regression and linear mixed model were used to investigate 
relationships between ED and EI with patient characteristics as covariates. In 
energy balance analysis systemic inflammation and survival were covariates. 
Quality of life (QoL) was assessed by questionnaire, physical function by 
treadmill test. 
Results: Diet ED was associated with EI, explaining approximately 16-22 % 
of the variation in EI. Age, BMI, fatigue and survival were negatively 
associated and hypermetabolism was positively associated with EI. After 
covariate adjustment, ED was still positively associated with EI. In 
unadjusted models, the ED of solid food and EI were both positive predictors 
of energy balance (P<0.03). Survival was positively and systemic 
inflammation negatively associated with energy balance (P<0.005). After 
adjustment for inflammation, only EI remained a significant predictor. 
Adverse QoL, function and symptoms were associated with weight loss >2%, 
BMI <20, fatigue and CRP >10mg/L (P<0.05). Short walking distance was 
associated with fatigue, low grip strength and inflammation (P<0.05). Short 
survival was associated with weight loss, fatigue, inflammation and S-
albumin < 32g/L (P<0.05). The prevalence of cachexia diagnosis varied from 
12 to 85 % using different definitions. 
Conclusions: Diet energy density and energy intake are positively 
associated. Age, BMI, fatigue, survival and hypermetabolism are associated 
  
with EI, but do not substantially influence the association between ED and 
EI. Diet EI and ED of solid food are positively associated with energy 
balance in patients with advanced cancer. Relations between EI, ED and 
energy balance are affected by systemic inflammation. Thus, targeting 
systemic inflammation may be important in nutritional interventions in this 
patient group. 
Weight loss, fatigue and markers of systemic inflammation were consistently 
associated with adverse QoL, reduced function, more symptoms and shorter 
survival. The prevalence of cachexia using different definitions varied 
widely; indicating a need to further explore and validate diagnostic criteria 
for cancer cachexia. 
Keywords: Cancer, cachexia, diagnostic criteria, quality of life, nutritional 
support, energy intake, energy balance, dietary energy density 
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Aptitlöshet och avmagring (kakexi) är vanligt vid avancerad cancer och 
förknippas med negativa konsekvenser så som försämrad behandlingseffekt, 
livskvalité, fysisk funktion och kortare överlevnad. Tydliga och välbelagda 
diagnostiska kriterier för kakexi saknas, vilket försvårar diagnostiken och 
behandlingen. Minskat födointag är en av de viktigaste faktorerna som leder 
till avmagring. Ett av de vanligaste kostråden för att öka energiintaget är att 
öka intaget av energirika livsmedel och drycker. Energitätheten i kosten kan 
påverka energiintag och energibalans positivt men detta är inte studerat på 
cancerpatienter. 
Syftet med denna avhandling var att studera om energitätheten i kosten kan 
påverka energiintag och energibalans hos patienter med avancerad cancer. Ett 
ytterligare mål var att utforska och validera olika diagnostiska kriterier för 
cancer cachexia genom att se hur dessa relaterar till nedsatt livskvalité, fysisk 
funktion och överlevnad. För att studera detta analyserades data från 
interventionsstudier av anti-inflammatorisk behandling, anemibehandling, 
insulinbehandling och näringsstöd på en palliativ öppenvårdsmottagning, 
Sahlgrenska Universitetssjukhuset, mellan 1993 och 2005. Mätningar 
inkluderade blodvärden, fysisk funktion, kroppssammansättning och 
livskvalitéformulär. Kostintaget uppskattades från kostdagböcker. 
Det fanns ett positivt samband mellan kostens energitäthet och energiintaget. 
Patienter med högre ålder, mer trötthet och kort överlevnad hade ett lägre 
energiintag men även hos dessa patienter var en hög energitäthet i kosten 
förknippat med ett högre energiintag. Ett högre energiintag och hög 
energitäthet i fast föda var förknippat med en förbättrad energibalans under 
de följande 4 månaderna. Patienter med inflammatoriskt påslag hade en mer 
negativ energibalans, vilket överskuggade energitäthetens påverkan. Dessa 
fynd stödjer nuvarande kostråd men belyser även vikten av anti-
inflammatorisk behandling. 
Viktminskning, trötthet och inflammatoriska markörer var förknippat med 
nedsatt livskvalité, funktion, fler symtom och kortare överlevnad. 
Förekomsten av kakexi varierade kraftigt beroende på vilka kriterier som 
användes, vilket indikerar ett behov av att ytterligare undersöka och validera 
diagnostiska kriterier för cancer kakexi.  
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AMC Mid-arm muscle circumference 
ASMI Appendicular skeletal muscle mass index 
BMI Body mass index 
BW Body weight 
CRP C-reactive protein 
DXA Dual-energy x-ray absorptiometry 
E% Percentage of energy intake 
ED Energy density 
EDfood Energy density of solid food 
EI Energy intake 
ES Effect size 
ESR Erythrocyte sedimentation rate  
FR Food record 
EORTC European Organization for Research and Treatment of Cancer 
Scale  
KPS Karnofsky Performance Score 
ONS Oral nutritional supplements 
QoL Quality of life 
REE Resting energy expenditure 
TSF Triceps skinfold 
WL Weight loss 
W% Percentage of food weight
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Cachexia is very common in patients with advanced cancer. It affects 
treatment, survival, quality of life (QoL) and function negatively, yet it is 
rarely recognized, assessed, or managed actively [1]. Contributing factors 
may be the lack of a clear definition and the multifactorial nature of the 
cachexia syndrome [1, 2]. Recently there have been several articles defining 
and discussing the definitions of cancer cachexia  [2]. The most accepted 
definition of cancer cachexia have been published as an international 
consensus and is one from more detailed descriptions of stages and subsets 
will develop [1, 2]. The currently suggested definitions and staging of cancer 
cachexia are supported by a clinical and pathophysiological rationale [1, 3-5]; 
however, the validity and prognostic significance in different patient groups 
remains limited [4, 6, 7]. 
Reduced food intake is one of the main domains of anti-cachexia therapy [1, 
2, 8-10]. Dietary counseling is in routine practice often recommended as the 
first line of nutrition therapy [11, 12]. One of the most common strategies to 
increase energy intake (EI) is to increase the intake of energy-dense food and 
beverages [11-14]. Dietary energy density (ED) is associated with EI in 
healthy and obese subjects [15-19]. The effect of dietary advice aimed at 
increasing ED in patients with advanced cancer has not been studied. This 
advice is consequently based on expert opinions and interventions in other 
patient groups [11-14]. 
The main objective of this thesis was to increase knowledge and efficacy of 
oral nutrition therapy by investigating if diet ED is important for maintaining 
an adequate EI in cancer patients (paper I-III). An additional objective was to 
further explore and validate different diagnostic criteria in the diagnosis and 
staging of cancer cachexia (paper IV). To achieve this, a secondary analysis 
was performed of data from intervention studies of anti-inflammatory 
treatment, anemia therapy, insulin treatment and nutritional support in an 
outpatient palliative care program at the Department of Surgery at 
Sahlgrenska University Hospital (Gothenburg, Sweden) between 1993 and 
2005 [20-23]. 
 
There were more than 55 000 cases of malignant cancers reported to the 
Swedish Cancer Registry in 2010. During the last two decades the average 
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annual increase in number of cases has been 2.0 % for men and 1.4 % for 
women. The increase is partly explained by the ageing population but also by 
the introduction of screening activities and improvements in diagnostic 
practices [24]. The probability of developing cancer before the age of 75 is 
31 % among men and 28 % among women. However, the risk of developing 
cancer varies strongly with both age and by site [24]. 
The prognosis for cancer patients in Sweden has developed positively in the 
last four decades. The relative 5-year survival has increased from 35 % for 
men and 48 % for women to nearly 70 % for both sexes [25]. 
The major gastrointestinal cancers are cancer of the colon, rectum and anus, 
stomach, pancreas and biliary tract. Together they constitute about 16 % of 
all newly diagnosed cancers in Sweden [24]. 
There is an annual decrease in incidence of upper gastrointestinal cancers for 
both men and women during the last two decades which is mainly attributed 
to a reduction in stomach cancer incidence [24]. Overall 5-year survival of 
stomach cancer is about 20 percent [25]. 
Cancer of colon and rectum are among the most common cancer sites and the 
trend is rather stable although colon cancer in women has increased during 
the last decade [24]. The relative 10-year survival rate is over 50 percent [25]. 
There is a declining trend in both cancer of the liver and pancreas. Cancer of 
the pancreas has very poor prognosis. The relative 5-year survival is currently 
only a few percent [25]. 
The main treatments for cancer care are surgery, radiotherapy and 
chemotherapy. Although the basic principles are the same, there is a constant 
improvement and refinement of these methods. Often they are combined in 
such a way that side effects are reduced, while treatment results are improved 
[25]. The disease and its treatment still generate a large number of symptoms 
that can affect nutritional status. All treatments have nutritional 
consequences, either because they add a nutritional demand or because they 
have side effects that limit dietary intake [26]. 
 
With long time (5-10 year) survival rates ranging from only a few percent to 
just over 50 % it is clear that a majority of patients with gastrointestinal 
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cancers are eligible for palliative care. The concept of palliative care and 
palliative medicine has been around for more than 30 years. The palliative 
phase begins from the moment cure is not or no longer possible, and lasts 
until the moment of death. The World Health Organization‟s current 
definition of palliative care states that:  
“Palliative care is an approach that improves the quality of life of patients and 
their families facing the problem associated with life-threatening illness, 
through the prevention and relief of suffering by means of early identification 
and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual”[27]. 
Palliative care is applicable early in the course of illness, in conjunction with 
other therapies that are intended to prolong life. As such it can include 
chemotherapy or radiotherapy, symptom management, nutrition support and 
counseling, preferably in a multimodal team approach [10, 26, 27]. The focus 
of care may change through the disease trajectory from physiological and 
functional outcomes to improvement of food enjoyment and QoL [26]. 
 
The term „cachexia‟ originates from the Greek words kakós (bad) and hexis 
(condition or appearance). This „bad condition‟ has long been associated with 
the gravely ill patient and with poor prognosis. The term is regularly used to 
describe wasting of body tissues or a state of depletion [26]. 
 
Cancer cachexia is a complex and multifactorial syndrome that is not easily 
defined and several definitions and criteria for diagnosis have been suggested 
[1-4, 6]. An ongoing loss of muscle mass (with or without loss of fat mass) 
due to a negative energy and protein balance driven by a variable 
combination of reduced EI, systemic inflammation and metabolic 
abnormalities are considered to be main characteristics [1, 2]. 
Development of cancer cachexia is seen as a continuum with three suggested 
stages that are clinically relevant: precachexia, cachexia and refractory 
cachexia [1]. Their definition still remains somewhat imprecise but provide a 
framework which can evolve over time [1, 2]. Defining the stage and 
components of cancer cachexia could help select patients suitable for 
multimodal treatment programs [1, 2, 10]. Early recognition of cachexia is 
important so that its effects can be reduced or postponed. The proportion of 
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patients with cachexia diagnosis can vary considerably depending on the 
definition criteria used [6, 7, 28, 29]. For example, Fox et al. observed a 
prevalence of cachexia ranging from 2.4 to 14.7 % depending on definition 
and totaling 23.1 % by any of these definitions in a large sample of cancer 
patients [29]. In weight losing patients with advanced pancreatic cancer the 
prevalence ranged from 21.8 to 60 % depending on if a 3 or 2 factor 
definition of cachexia were used [4]. Thoresen et al. observed a prevalence of 
cachexia ranging from 22 to 55 % in colorectal cancer patients depending on 
definition [7].  Bozzetti et al. classified patients by 4 classes (or stages) of 
cachexia from „asymptomatic precachexia‟ to „symptomatic cachexia‟ based 
on weight loss (WL) (≥10%) and presence or absence of symptoms; 36 % 
had both symptoms and WL, 40 % had WL and 83 % had either WL or 
symptoms, leaving 17 % with WL <10% and no symptoms [6]. The 
prevalence of „nutritional risk‟ or „malnutrition‟ in cancer patients varies 
widely, ranging from 5 to 85 %, using different criteria (WL, BMI or 
screening instruments) in different populations and settings [11]. It is clear 
that a lack of definition and classification is a barrier to getting a clear picture 
of the prevalence and consequences of cachexia. 
Diagnostic criteria should be both sensitive and specific to be of value in 
clinical practice and in the design of clinical trials. The currently suggested 
definitions and staging of cancer cachexia are strongly supported by a clinical 
and pathophysiological rationale [1, 3-5]. However, the validity and 
prognostic significance in different patient groups remains limited [4, 6, 7]. 
 
Cachexia in advanced cancer has a negative impact on outcomes such as 
QoL, physical function and survival [1, 5, 30]. Approximately 20% of 
patients with cancer may die from the effects of malnutrition rather than the 
malignancy [31]. Cachexia is also associated with increased risk of 
complications in surgery and radiotherapy and impaired response to 
chemotherapy [31, 32].  
Weight loss is a cardinal feature of cancer cachexia and a majority of patients 
with advanced cancer experience some degree of WL [5]. Weight loss is a 
significant prognostic variable for survival in most studies in patients with 
advanced cancer [33]. Various perspectives exist on how to classify WL. 
Absolute WL can be classified by severity and various cut-offs have been 
suggested, from 2 to >20 % [1, 26]. Another perspective is intensity of WL, 
i.e. rate of WL in 1 week, 1, 3 or 6 months [1, 26]. Body mass index (BMI) 
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can be a measure of body energy and protein reserves, and can together with 
WL be used to assess the severity of depletion [1]. However, none of these 
classifications take into account the wide distribution in body composition in 
cancer patients and also give no information of proportions of fat and lean 
body mass lost [26]. 
Weight loss reflects a negative energy balance, in which dietary EI is less 
than energy expenditure. A reduced EI due to anorexia and metabolic 
abnormalities, including hypermetabolism driven by systemic inflammation, 
are considered the primary causes [5, 30, 34]. Other procachectic 
mechanisms may, however, be involved. 
Weight loss is composed of lean and adipose tissues in different degrees.  
The amount of WL for any unit of energy deficit will be highly dependent on 
the proportion of fat and fat free mass lost as their energy density are very 
different (9,417 kcal/kg for fat and 884 kcal/kg for fat-free mass) [35]. The 
low energy content of lean tissue and concomitant up regulation of 
proteolytic pathways (particularly the ubiquitin-proteasome pathway) 
together with hypoanabolism makes loss of muscle mass greater than 
expected for any level of energy deficit compared to healthy subjects [36-39]. 
Systemic inflammation is believed to be primarily involved in the metabolic 
change and loss of muscle in cachexia; hormones, tumor derived factors, bed 
rest, and inadequate nutrient intake may also contribute [10, 40]. 
The ensuing loss of function and debilitation makes muscle loss an important 
feature and treatment target in cancer cachexia [1, 10, 37]. Muscle loss is 
indeed associated with poor outcome and shorter survival in cancer patients 
[41]. 
Assessment of muscle mass and strength are therefore important in diagnosis, 
staging and follow-up of cachexia; however, there is no consensus as to 
methodology [1, 42]. Cross-sectional imaging has been suggested as the 
preferred method (CT or MRI), followed by dual-energy x-ray 
absorptiometry (DXA), mid-arm muscle circumference (AMC) and 
bioimpedance analysis [1]. Handgrip strength has been suggested as the 
preferred method assessing muscle function [1, 3, 42]. There is also no clear 
consensus as to which cut-off limits should be used in diagnosis of cachexia. 
Appendicular skeletal muscle mass index (ASMI) consistent with sarcopenia 
have been suggested when using DXA [1, 3]. 
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The catabolic drive and metabolic abnormalities in cancer cachexia has long 
been considered to be the result of a variety of interactions between the tumor 
and the host, of which all are not completely understood [38, 39]. The tumor 
induces local production of pro-inflammatory (interleukins; IL-1, IL-6, IL-8, 
interferon-γ and tumor necrosis factor-α) and anti-inflammatory cytokines 
(IL-4, IL-10 and IL-13) as well as tumor specific cachectic factors 
(proteolysis inducing factor and lipid mobilizing factor) [38, 39]. The liver 
responds by increasing the production of positive acute-phase proteins such 
as C - reactive protein (CRP) and fibrinogen. Concomitantly the level of 
albumin, a negative acute-phase protein, may fall [38]. Although not 
completely understood, there also seems to be a neuro-endocrine stress 
response that results in inadequate neuro-hormonal anabolic activity (insulin, 
growth hormone and testosterone) and excess catabolic activity (cortisol and 
myostatin) [38]. These host tumor interactions results in a catabolic state with 
a deranged protein, lipid and glucose metabolism [38, 39]. Systemic 
inflammation measured by CRP is associated with WL and poor prognosis 
[5, 43]. The value of specific cytokines in the assessment of inflammation in 
cachexia needs further study [5, 10]. Systemic inflammation is therefore 
considered to be one of the key features of the cachectic state and an 
important therapeutic target [1, 10, 38].  
The most common marker of systemic inflammation in cancer patients has 
been the level of CRP [1]. Two cut-off levels have been suggested, CRP >5 
or >10 mg/L [3, 4]. Alternative markers and prognostic scores include 
erythrocyte sedimentation rate (ESR), serum albumin, the composite 
Glasgow Prognostic Score, the Neutrophil Lymphocyte Ratio or the Platelet 
Lymphocyte Ratio [22, 43, 44]. Additional work is required to establish the 
value of different measures of inflammatory response as diagnostic criteria 
and selection in clinical trials [1, 43] 
Many different anti-inflammatory therapies have been used in cancer 
cachexia treatment. Therapies include celecoxib, indomethacin, 
eicosapentaenoic acid, ibuprofen and thalidomide. The effects have generally 
been positive but inconsistent and few studies have been carried out that 
compared treatments [45-52]. Lundholm et al. showed that indomethacin 
prolongs survival over that achieved with placebo, but the effect of 
prednisolone is less clear [46]. Mantovani et al. showed that a combination of 
a progestational agent, eicosapentaenoic acid, L-carnitine and thalidomide is 
more effective in improving lean body mass, resting energy expenditure 
(REE) and fatigue reduction than any of the agents given alone [53]. 
Similarly, a combination of fish oil and COX-2 inhibitors is more effective in 
Ola Wallengren 
7 
improving weight and strength than fish oil alone [48]. It is clear that further 
study is needed to determine the most effective mode of anti-inflammatory 
treatment. 
Loss of appetite is one of the most frequently reported symptoms in cancer 
patients with on average 65 % of patients reporting anorexia in studies of 
palliative care [5, 26, 33]. Neuroendocrine and metabolic control of EI and 
appetite is regulated by peripheral signals to the brain as well as signaling of 
metabolic sensors in the brain and brainstem. It is clear that cancer anorexia 
is multifactorial and involves most of the signaling pathways modulating EI 
[26, 39]. The influence of anorexigenic signals is dominating and the 
orexigenic signals are reduced so that anorexia develops and EI is reduced 
[26, 39]. However, reported anorexia is not always associated with reduced 
intake and WL and vice versa [5].  
Reported energy intakes by cancer patients are generally low. Average 
energy intakes are close to reported basal energy expenditure [26, 54, 55]. As 
a consequence a significant number of patients consume less energy than is 
required for basal activities of daily living. Energy intake is associated with 
WL in several but not all studies [5]. As a diagnostic criteria an EI < 1500 
kcal/day have been used classifying patients with low intake [4]. Patients 
own estimate of intake in relation to normal have also been suggested for 
assessment of overall food intake [1]. 
Increased energy expenditure would also contribute to a negative energy 
balance. Resting energy expenditure has been measured in a variety of 
studies and results have been variable [5, 39]. Increased, normal and 
decreased metabolism has all been found [5, 39, 56]. Hypermetabolism may 
be present in some patients and it has been related to type and stage of tumor 
and the presence of systemic inflammation [5, 34, 39]. Total energy 
expenditure may fall due to reductions in physical activity, compensating for 
reduced EI and any hypermetabolism [57, 58]. Interestingly, it is possible to 
increase total energy expenditure with oral nutritional supplements (ONS) 
containing eicosapentaenoic acid [58]. 
Many drugs have been evaluated for their appetite stimulating properties and 
effect on EI, including progestins, glucocorticoids, cannabinoids and ghrelin 
[59-62]. There are some improvements in appetite, EI and body weight 
(BW); however, several of these drugs have unwanted side effects and no 
clear benefit towards QoL or survival have been observed which limits their 
clinical usefulness [10, 26, 59-62]. 
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A number of symptoms may limit food intake in patients with advanced 
cancer, such as; anorexia, pain, early satiety, nausea, vomiting, dry mouth, 
dysphagia, dysgeusia, constipation and others, caused by the disease itself or 
by treatment [26, 63]. Many of these nutrition impact symptoms are present 
concurrently and psychological factors, such as anxiety, depression and 
distress, may also contribute [26]. Anorexia, dysphagia, pain and mouth sores 
are associated with reduced dietary intake, WL and reduced functional 
capacity [63]. Anorexia, dysphagia, nausea, pain, constipation and depressed 
mood are also associated with shorter survival [33, 64]. Many of these 
symptoms can be treated or palliated and there is a need of an integrated 
approach of these symptoms in the assessment and treatment of cancer 
cachexia [1, 26, 33]. 
The cachexia syndrome has detrimental effect on QoL. Patients report an 
impact on their emotions, spirituality, relationships and social functioning. 
Together with anorexia, pain and fatigue this results in a restricted and 
isolated life with decreased performance status and QoL [4, 26, 63, 65, 66]. 
Reduced QoL is associated with shorter survival [64]. There is a significant 
correlation between physical activity levels and patient reported physical 
function, role function and fatigue [57, 67]. Nutritional status is also 
associated with QoL and function and these aspects can also improve with 
nutritional interventions [65, 68-70].  
Fatigue is one of the most common symptoms for patients with advanced 
cancer [33]. Fatigue can be defined as a subjective feeling of tiredness, 
weakness or lack of energy [71]. It is a multidimensional syndrome of 
physical, cognitive and emotional components with difficulty in motivation 
or in activity. The exact cause of fatigue remains unclear and many 
contributing factors may exist, such as energy depletion, alterations in muscle 
metabolism, pro-inflammatory cytokines, anemia, endocrine disorders, 
infections, medications, depression, and other interfering symptoms [42, 71, 
72]. Pharmacological interventions for fatigue have shown some effects of 
psychostimulant methylphenidate, erythropoietin and darbepoetin [73]. Non-
pharmacological interventions support the use of exercise and psychosocial 
interventions in the management of cancer related fatigue. Overall, more 
research is warranted, especially to determine potential efficacy in those with 
advanced disease [73]. 
Patient centered outcomes, such as patient reported QoL, function and 
symptoms, are important aspects when assessing the impact of cachexia and 
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effects of anti-cachectic treatment [1, 74, 75]. In palliative care, QoL and 
function becomes the principal or only endpoint of consideration [27, 74, 75]. 
The European Organization for Research and Treatment of Cancer 
questionnaire (EORTC-QLQ-C30) [76] is recommended in the routine 
assessment functional and psychosocial effects [1]. Alternatively, physician 
reported performance status can also be used (e.g. Karnofsky performance 
score or Eastern Cooperative Oncology Group questionnaire) [1, 77, 78]. 
Objectively measured physical activity with activity meters can be used to 
assess physical function, may provide a surrogate marker of QoL and is a 
meaningful outcome in clinical trials [1, 37, 57]. 
 
The overall goal of oral nutritional support to cancer patients is to maintain or 
improve nutritional status and thereby improve treatment tolerance and 
outcome. Additional goals are to reduce disease or treatment symptoms, 
maintain or improve functional capacity and ultimately improve the patient‟s 
QoL [11-13, 68, 79-82]. Nutrition support in curative treatment aims 
primarily at increasing treatment tolerance [26, 65]. In the palliative phase, 
the main goal is to alleviate and prevent adverse symptoms and maintain or 
increase QoL [26, 65]. For caregivers involved in decisions related to 
nutritional support in patients with advanced cancer it is important to keep 
aware of the current state of evidence concerning prognosis in this patient 
group [26]. Approximation of life expectancy is required to make appropriate 
decisions in the phases of advanced malignant disease [26]. 
When ad libitum dietary intake is inadequate there are a number of nutrition 
support strategies available; dietary fortification and counseling, oral 
nutritional supplements (ONS, ready to drink or reconstituted powder), 
enteral tube feeding and parenteral nutrition, alone or in combination [11]. 
Conventional nutrition support cannot fully reverse the loss of muscle or the 
ensuing functional impairment in cachectic patients [1, 9]. However, 
multimodal treatment including nutrition support and anti-inflammatory 
treatment has been shown to partially alter the cachectic trajectory, improving 
functional capacity, QoL and prolonged survival of advanced cancer patients 
[20, 49, 53, 68, 83]. End stage catabolic patients with severe muscle wasting, 
low performance status and unresponsive to oncological treatment may not 
have clinical important benefits from such multimodal treatments [1]. 
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European, American and Australian guidelines on nutritional support to 
cancer patients recommend that nutrition receives prompt attention and that 
intervention is commenced in patients that are malnourished or at risk for 
developing malnutrition [79-82, 84]. However, these guidelines do not fully 
capture the potential benefits of oral nutritional support such as dietary 
counseling and ONS as they rely predominantly on data from studies of 
enteral or parenteral feeding [68]. 
 
Nutrition counseling is a supportive process, characterized by a collaborative 
counselor–patient relationship, to set priorities, establish goals, and create 
individualized action plans that acknowledge and foster responsibility for 
self-care to treat an existing condition and promote health [85]. 
Dietary counseling to improve nutrient intake in cancer patients with 
declining nutrient status is in routine practice often recommended as the first 
line of diet therapy, prior to using ONS or in combination with ONS [11, 12]. 
Dietary counseling should be individually tailored to nutritional needs, 
nutritional status, dietary restrictions, tolerance and feasibility, 
gastrointestinal function, medical condition and expected side effects of 
treatment [11, 12]. There are various dietary counseling strategies to support 
oral nutrient intake, including increasing the intake of energy-dense food and 
beverages, increasing the frequency of meals and snacks, enhancing flavor, 
modifying texture or temperature, limit beverage or separate food and 
beverage intake, retry problem foods, take alcohol as an appetite stimulant 
and avoid or include foods to remedy symptoms [11-14]. An alternative 
approach is to not increase quantity, avoid nutritional supplements or be 
allowed not to eat and that dietary restrictions should be lifted [13]. 
Psychosocial targeted advice includes eating what you want, can tolerate, are 
easy to eat, enjoy and that will improve QoL. Some suggest relaxing dietary 
restrictions and eat whatever negotiated as best by patient and family [13]. 
Most of these advices are based on expert opinions with little theoretical 
justification or empirical evidence to support them [13]. Some are based on 
observational studies, non-randomized trials or interventions in other patient 
groups [11-14]. Many studies neglect to report or give very brief information 
about the person giving the dietary counseling, frequency of counseling, 
which specific advices that were given, counseling methods used or the 
patients understanding and compliance. Most importantly, randomized trials 
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comparing the effects of specific dietary advice and their relative efficiency 
in cancer patients are lacking [11-13]. Consequently, little well supported 
specific dietary counseling strategies aimed at improving dietary intake in 
cancer patients are available. This is an area for further study. 
 
Energy dense foods are used with the intent of increasing the ED of the diet 
and thereby increase EI. Small meals, in reference to weight and volume, 
with high ED will provide more energy and are supposed to be less satiating.  
Diet energy density is positively correlated with EI in healthy and obese 
people, both in experimental studies and in studies of people eating 
self-selected diets in free living conditions [15-19]. Cross-sectional 
epidemiological studies have shown that ED and BMI are correlated and that 
ED is associated with weight or waist circumference [86, 87]. This result, 
while not a general finding, implies that ED is associated with long-term 
energy balance in healthy and obese people [86, 87]. 
Experimental studies in institutionalized elderly or with home-delivered 
meals have shown that EIs increase when ED of the diet are increased [88-
91]. However, these were not self-selected diets and all or a large part of the 
diet were manipulated and supplied to the subjects. This limits the potential 
for compensatory changes in intake and may not reflect the long term impact 
of diet ED on energy balance in the context of dietary counseling. With 
increased ED of the diet a decrease in the amount (weight) of food is usually 
observed so that EI increases less than expected (i.e. food intake 
compensation) [11, 15, 19, 92, 93].  
The effect of dietary advice aimed at increasing ED in patients with advanced 
cancer eating self-selected diets in free living conditions has not been studied. 
Dietary counseling to increase the intake of energy-dense foods may be 
inappropriate for patients with advanced cancer, if it does not result in 
increased EI and an improved energy balance. This may be the case, for 
example, if the patient makes compensatory changes. 
Dietary energy density can be defined as the energy per unit of dry or wet 
weight of food or energy per unit of volume of food. Usually ED is defined 
as energy per wet weight of food eaten [19]. The energy density of the diet is 
dependent on the macronutrient composition, amount of water, fiber and air 
in the diet, where the amount of water and fat is of most practical importance 
[94]. 
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Different methods of ED calculation have been used, in reference to the types 
of food included in the analysis [95, 96]. The energy density can be markedly 
affected by the inclusion or exclusion of specific dietary items, particularly 
energy-free beverages [94-96]. This has implications for making direct 
comparisons between studies and interpretation of findings. In addition, 
associations between ED and dietary intake could vary according to how ED 
was calculated and therefore make the results of such studies method-
dependent [87, 95]. For example, studies in healthy subjects have shown that 
ED is associated with long-term energy balance but the association depends 
on whether water and less energy-dense drinks are included in the calculation 
[87]. Research on healthy subjects suggests that energy-free beverages do not 
influence EI, though the long term effects of non-energy beverages intake on 
EI have not been fully explored [19, 97-99]. 
There is also limited information on the influence of patient characteristics on 
the association between ED and EI, potentially hampering individual 
tailoring of dietary treatment in clinical practice. In a heterogeneous sample, 
dietary associations in a between- or within-subject analysis could be 
different, due to differences among subjects such as age, sex, BMI, physical 
activity level, dietary reporting levels and related measurement errors (i.e. 
attenuation bias)  [19, 100, 101]. 
Clarification of the association between ED, EI and energy balance in 
patients with advanced cancer is, therefore, necessary to improve dietary 
advice. 
 
To review the evidence base for oral nutritional support to cancer patients 
meta-analyses, evidence based guidelines, systematic reviews and their 
bibliographic references were searched to identify studies that studied the 
effectiveness of oral nutritional support in cancer patients compared to no 
advice or usual care [11-13, 68, 79-84, 102-105]. Searches were updated with 
PubMed searches with combinations of exploded MeSH terms including 
neoplasm, diet therapy and nutritional support and related search terms. Only 
human randomized controlled trials (RCT) in English or Nordic languages 
were included. Trials studying the effects of parenteral or enteral nutrition or 
specific nutraceuticals (e.g. EPA, arginine, and glutamine) were excluded. 
Twenty-two RCTs with a total of 1847 participants were found [106-127]. 
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Study groups were: 
 no advice 
 usual care 
 the prescription of ONS 
 dietary counseling 
 dietary counseling and ONS 
 
The no advice or usual care groups were control groups. However, usual care 
included brief nutritional advice, written or by dietician or other health care 
professionals in some studies. Oral nutritional supplements were 
commercially available ready to drink sip feeds but also creams or 
reconstituted powders that were nutritionally complete or energy/protein 
dense with vitamin and minerals. Amounts of ONS prescribed were not 
specified in all studies but ranged from 400 to 2400 kcal [106, 124, 125]. 
Four studies compared elemental or hydrolyzed diets to standard diets in 
patients with abdominal radiation [106-109]. In the 19 studies that included 
some form of dietary counseling or usual care with dietary information this 
was performed by a dietician in 13 studies [110, 113, 114, 118-127], 
otherwise it was performed by other health care professionals or not 
specifically mentioned. In most studies, the dietary counseling strategies used 
were only briefly described and focused mainly on increasing the intake of 
energy-dense food and beverages, increasing the frequency of meals and 
snacks, modifying texture and to avoid or include foods to remedy 
symptoms. 
Overall there were several clinical benefits of the interventions including: 
 Improved energy and protein intake [111, 113, 115, 119, 
121, 123-125, 127] 
 Improved body weight and anthropometry [106, 112, 117, 
118, 122, 123, 126] 
 Less malnutrition [120, 123-125] 
 Improved immune function [106, 107] 
 Improved QoL and function [124, 125] 
 Less symptoms [116, 124, 125] 
 Less complications or improved treatment tolerance [114, 
117, 127] 
 Reduced length of stay in hospital [114]. 
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Effects of the interventions were mixed and 3 studies did not find any 
significant effects at all [108-110]. Two of these were comparisons of 
elemental diet for 33-44 days to standard low fiber diet; however, in 2 similar 
trials there were improvements in weight and immune function [106, 107]. 
The 3
rd
 study included only well-nourished patients where positive effects are 
less likely [11, 110]. In the largest study, comparing dietary counseling, ONS 
or their combination to a control group, only modest effect on weight were 
found in the counseling group with no other effects of the interventions 
[126]. However, compliance to nutritional support was very low, for 
example; only 19% of patients were able to take their full prescription of 
ONS by week 6 of the 1 year study and only 17% completed more than one 
food diary [126]. 
In the most recent meta-analysis of the effects of oral nutritional support in 
cancer patients 13 randomized controlled trials with 1414 participants were 
included [68]. There were no significant differences in mortality between 
intervention and control groups (RR 1.06, P =0.43, I
2
=0%). Nutritional 
intervention had positive effects on some measures of QoL and symptoms 
(global QoL, emotional functioning, dyspnea and anorexia). There were 
significant improvement in BW (mean difference 1.86 kg, P =0.02, I
2
=76%) 
and EI (mean difference 432 kcal/day, P =0.001, I
2
=97%). Heterogeneity 
was high in all significant analyses. Studies showing larger effects were 
identified as sources of heterogeneity [123-125]. Consequently, after 
removing these studies no significant effects were found.  
In a previous meta-analysis with 3 studies [107, 111, 115], of which 2 were 
not included in the above meta-analysis, found that oral nutrition support 
increased EI by 381 kcal/day, without significant heterogeneity [83]. 
The several positive effects of oral nutritional support in cancer patients are 
also supported by meta-analyses in other patients groups that have 
consistently shown improvements in nutrient intake, anthropometry and also 
a number of clinical and functional benefits [11, 102, 104, 105]. Contrary to 
studies in cancer patients, meta-analyses in several other patient groups have 
repeatedly shown reductions in hospital admissions and mortality [11, 104, 
105]. However, the most recent Cochrane review did not find a consistent 
effect on survival [102]. Most studies in cancer patients are not adequately 
designed or powered to study the effects on mortality. For example, Baldwin 
et al. aimed at a assessing the effects of nutritional interventions on survival. 
They intended to include 660 patients to reach adequate power but the study 
was stopped prematurely by advice of a data monitoring committee and only 
included 358 patients and only half of the predicted deaths had occurred 
[126]. 
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There are inherent difficulties studying the effects of nutritional 
interventions. Failure to comply with the treatment, lack of blinding and 
patients obtaining dietary information from alternative sources all make it 
difficult to assess the true treatment effect and also decrease the effect size 
(ES) of the interventions [128]. With these methodological issues and the 
large clinical heterogeneity between studies in mind, it is not surprising that 
results are heterogeneous and effects are modest or insignificant. 
Consequently, it is not yet possible to determine whether this is due to failure 
of the interventions, due to poor compliance or different effects in diverse 
patient groups and settings. 
In conclusion, oral nutritional support to cancer patients is effective at 
increasing nutritional intake and BW and can also improve some aspects of 
QoL and malnutrition related outcomes. No beneficial effects on mortality 
have been found. Available evidence suggests that oral nutritional support 
should include dietary counseling with ONS if needed. Few well supported 
specific dietary counseling strategies aimed at improving dietary intake in 
cancer patients are available. The effects of diet ED on EI and energy balance 
have not been specifically studied. Conclusions are clearly limited by the 
large clinical and statistical heterogeneity and the low to moderate quality 
data from available studies. Further studies are needed. 
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The overall aim of this thesis was to investigate if the energy density of the 
diet is important for maintaining an adequate energy intake in cancer patients. 
The thesis also aimed to examine which patient characteristics that may 
influence dietary intake, all in order to increase knowledge and efficacy of 
nutrition therapy for disease-related malnutrition in cancer patients. 
An additional aim was to study the relation between different diagnostic 
criteria for cancer cachexia and the prevalence of adverse patient centered 
outcomes such as reduced QoL, impaired function, symptoms and also the 
prognostic significance of these criteria on survival. 
Specifically, the following questions were addressed:  
1. Is diet ED associated with EI in palliative care cancer 
patients? (paper I) 
2. Which method of diet ED calculation is most appropriate to 
describe a possible relationship between EI and ED? (paper 
I) 
3. In addition to diet ED, what subject characteristics (i.e. sex, 
age, BMI, WL, muscle mass, hand grip strength, fatigue and 
inflammation) are associated with EI? (paper II) 
4. Do subject characteristics associated with EI influence the 
association between EI and diet ED? (paper II) 
5. Is the association between ED and EI different within 
individuals compared to group level associations when 
accounting for between subject differences? (paper II) 
6. Is diet ED and EI associated with energy balance in patients 
with advanced cancer, and does systemic inflammation 
influence these possible relationships? (paper III) 
7. Which diagnostic criteria of cancer cachexia are associated 
with reduced QoL, more symptoms, reduced functional 
abilities and shorter survival? (paper IV) 
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Patients referred to a palliative care program at the Department of Surgery at 
Sahlgrenska University Hospital (Gothenburg, Sweden) between 1993 and 
2005 were included in the studies. This was a secondary analysis of cross-
sectional and longitudinal data from intervention studies of anti-inflammatory 
treatment with indomethacin, of anemia with erythropoietin, insulin 
(NCT00329615), dietary counseling and nutritional support in an outpatient 
palliative care program. [20-23]. Patients were invited to participate in 
follow-up measurements that included biochemical tests, measurement of 
body composition and dietary intake every 4 months. None of the patients 
received radio- or chemotherapy during follow-up or had received any of 
these therapies within 6 months of the start of our evaluations. 
Inclusion criteria were the presence of generalized malignant disease with a 
solid tumor type without efficient or established tumor treatment available, 
expected survival of more than six months at first visit. Subjects were also 
required to have data for BW, height and WL from pre-illness weight. In 
paper I, II and IV baseline data at inclusion in the above mentioned studies 
were used for analysis. In the longitudinal follow-up, all available data that 
met the study criteria were used for analysis. Measurement of REE was 
required in paper I. For inclusion in paper I-II at least one food record (FR) 
was required. The completion of at least two measurements of body 
composition and FRs separated by 4 months were required for the 
longitudinal follow-up (paper III). For paper IV at least one outcome was 
required (quality of life questionnaire or a treadmill walk). Exclusion 
criterion was treatment with parenteral or enteral nutrition at inclusion (paper 
I, II and IV) and during follow-up (paper III). Outliers for EI (outside ± 3 
SD) were excluded in paper II. Only patients with a complete data set were 
included in paper I. In paper II and III only patients with complete data in the 
mixed models are presented. An overview of design and analysis is presented 
in Table 1. 
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Table 1. Design and analysis. 
Paper I II III IV 
Design Secondary 
analysis 
Cross-sectional 
Secondary 
analysis 
Cross-sectional 
Secondary 
analysis 
Longitudinal 
Secondary analysis 
Cross-sectional 
Participants (n) 259 251 107 405 
Inclusion year 1993-2000 1993-2005 1993-2005 1993-2005 
Measurements Weight 
Height 
Pre-illness 
weight 
4 day FR 
REE 
Weight 
Height 
Pre-illness 
weight 
≥3 day FR 
REE 
DXA 
Survival 
Fatigue (1-10) 
Grip-strength 
Albumin 
CRP 
 
Weight 
Height 
Pre-illness weight 
≥3 day FR 
REE 
DXA 
Survival 
CRP 
ESR 
Weight 
Height 
Pre-illness weight 
≥3 day FR 
REE 
DXA 
AC  
TSF 
Survival 
EORTC-QLQ 
Fatigue (1-10) 
KPS 
Grip-strength 
Treadmill 
Albumin 
CRP 
ESR 
Exclusion 
criteria 
PN/EN PN/EN 
EI outliers 
(±3SD) 
PN/EN PN/EN 
Statistical 
analysis 
Linear 
regression 
Mixed model 
with repeated 
measures 
Mixed model 
with repeated 
measures 
Logistic 
regression, Cox 
proportional 
hazards model 
Abbreviations: AC, mid-arm circumference; CRP, C-reactive protein; DXA, dual-energy x-ray 
absorptiometry; EN, enteral nutrition; EORTC-QLQ, European Organization for Research and 
Treatment of Cancer Scale; ESR, Erythrocyte sedimentation rate; FR, food record; KPS, 
Karnofsky Performance Score; PN, parenteral nutrition; REE, resting energy expenditure; 
TSF, triceps skinfold. 
 
 
Body weight (BW) was recorded in light indoor clothing on a calibrated 
electronic scale. Habitual weight before the onset of disease was reported by 
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the patients. Weight loss was calculated as the difference between the two, 
and expressed as percentage of habitual BW. Body height was measured 
using a wall-mounted stadiometer and body mass index (BMI) was calculated 
as weight (kg) divided by height (m) squared. Weight loss and BMI were 
classified according to five different criteria; BMI < 20, WL > 2%, 5%, and 
10% respectively or WL > 2% and a BMI < 20 [1, 28].  
Body composition was measured by dual-energy X-ray absorptiometry using 
a LUNAR DPX-L scanner (Scanexport Medical, Helsingborg, Sweden). 
Whole-body scans were obtained in fast-scan mode. Body fat and lean tissue 
mass were analyzed using the extended research mode of the LUNAR DPX-
L software (Version 1.31; Scanexport Medical). Appendicular skeletal 
muscle mass index (ASMI) calculated from appendicular lean soft tissue 
mass (kg) divided by squared body height were used as a proxy of whole 
body skeletal muscularity. Low ASMI was defined as ASMI < 7.26 kg/m2 
for males and < 5.45 kg/m2 for females [1, 3]. Alternatively, AMC was used 
with a cut-off below the 10th percentile of a reference population [3, 129]. 
AMC was estimated using triceps skinfold and mid-arm circumference, 
measured with a Harpenden skinfold caliper and tape measure at midpoint of 
the humerus. Low muscle mass was defined as low ASMI or AMC below 
cut-off. 
Resting energy expenditure (REE) was measured by indirect calorimetry 
(Deltatrac; Datex, Helsinki, Finland) after an overnight fast. 
Hypermetabolism was expressed as the percentage of measured REE above 
or below the predicted basal metabolic rate using the Harris-Benedict 
equation. 
Energy balance was estimated from the difference in body composition from 
DXA scans separated by 4 months. Changes (gain or loss) in fat or fat-free 
mass were multiplied by their respective energy value (9,417 kcal/kg for fat 
and 884 kcal/kg for fat-free mass) and divided by the number of days 
between scans, giving energy balance per day (kcal/day) [35]. 
 
A dietician instructed the patients to complete a 4-day FR at home. Amounts 
of all food and beverages were recorded in household measures. The dietician 
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interviewed each patient and any ambiguities were resolved upon return of 
the FRs. The emphasis in dietary intake during the study of palliative 
nutritional intervention in addition to indomethacin and erythropoietin 
treatment had been on energy and macronutrients [20]; consequently, the 
recording of beverages that did not contain energy was not specifically 
requested. Estimation of serving sizes and conversion to weight units were 
aided by a previously validated meal model [130]. Intakes of energy and 
nutrients were calculated with KOSTSVAR (from 1993 to 2000) or with 
DIET32 (from 2000 to 2005) software (Aivo, Stockholm, Sweden). The 
National Food Composition table (PC-kost, Statens livsmedelsverk, Uppsala, 
Sweden) was used as nutrient database. Food records were validated by 24 
hr. urinary nitrogen [56]. 
Energy intake is reported in absolute amounts (kcal), amount per kg of BW 
(kcal/kg/d), and as a multiple of the measured REE (EI/REE). Macronutrient 
intake is reported as the percentage of EI (E%). Food weight, water volume 
and fiber weight are expressed in grams per day and as percentage of the total 
food weight (W%). 
“Energy density” is defined as the amount of energy per wet weight of food 
(kcal/g). Four different methods, with varying exclusions of different 
beverages and water, were used to calculate the ED in the diet: (ED1) all food 
and beverages (paper I-IV); (ED2) all food and energy-containing beverages 
(paper I); (ED3; EDfood) all food and milk (paper I and III); and (ED4) food 
only (paper I). These methods have previously been used by Cox and Mela, 
and were used here in slightly modified form, in that alcoholic beverages 
were excluded in ED3 and no analysis were performed on all dry matter and 
macronutrients [95]. In paper III ONS were also included in calculation of 
EDfood (ED3). Summaries of methods and the rationale for different 
calculations of ED are presented in Table 2. The food and beverages were 
grouped in accordance with Swedish National Food Composition Tables 
grouping of foods [131]; in addition, a food group was created for energy-
free beverages. 
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Table 2. Methods of energy density calculation. Methods presented in the 
order of least exclusion of food items. 
Method Includes Excludes Rationale 
ED 1 Total dietary 
intake 
- Typical dietary measure. 
Includes all on the 
assumption of a complete 
dietary record.  
ED 2 All food and 
energy-containing 
beverages 
Energy-free beverages, e.g. 
water, tea, coffee and non-
energy sweetened soft drinks 
Between meals beverage 
intake could be 
incompletely recorded. 
Uncertain to what extent 
non-energy beverages 
affect energy intake. 
ED 3 
(EDfood) 
All food and milk 
(ONS) 
All other beverages than milk Milk is consumed both as 
food and as a beverage. 
ED 4 Food only All beverages Exclusion of beverages can 
presumably decrease CV 
Abbreviations: CV, coefficient of variation; ONS, oral nutritional supplements. 
 
Blood tests included measurement of C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), S-Albumin and hemoglobin (Hb) levels. The 
presence of inflammation was defined by two criteria: 1/ An elevated level of 
CRP (three levels: CRP > 5, CRP > 10, CRP > 15 mg/L) or 2/An elevated 
ESR (two levels: > 20, > 30 mm/h). The Glasgow Prognostic Score (GPS) 
was also used to define whether inflammation was present [43]. 
Hypoalbuminemia was defined as S-Albumin < 32 g/L and anemia as Hb < 
120 g/L [3, 28]. 
 
Karnofsky Performance Score was assessed by the attending clinician and a 
score of 80 was used as cut-off [4, 77]. Grip strength was measured with a 
hand-held spring-loaded dynamometer. Low muscle strength was defined as 
a value in the lowest tertile, adjusted for sex and age [3]. Walking distance 
was measured on a treadmill. The exercise started with patient standing on 
the treadmill with all equipment connected for 1 min and thereafter walking 
1.5 km/h for 2 min. The test continued with walking at 1.5 km/h at a 12% 
elevation for 1 min; thereafter, the speed was increased 0.1 km/h every 10th 
second until the person finished the test. Patients with reduced walking 
capacity were defined as having walking distance less than the patient group 
mean, adjusted for sex and age. 
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The European Organization for Research and Treatment of Cancer (EORTC) 
QLQ-C30 form were filled out by the patient. The QLQ-C30 was developed 
for cancer patients and has been validated in multicultural environments [76]. 
It considers several factors that contribute to QoL, including physical and 
role functioning, cognitive status, emotional and social factors and global 
QoL. Symptoms (fatigue, pain, nausea and vomiting, dyspnea, and insomnia) 
and financial implications are also included in this questionnaire. Answers to 
specific items were summed and transformed linearly to range between 0 
(representing poor health) to 100 (representing optimal health status). Higher 
scores on the symptom scales indicate a high level of symptoms. 
Cluster analysis with a two cluster solution was used to identify relatively 
homogenous groups of patients into QoL and symptom clusters. Primary 
outcome were a “QoL and symptom” cluster where all functional and 
symptom scales and items, except financial implications, were used to form 
two clusters with patients differing in these two aspects. In addition, two 
more cluster analyses were run with only QoL and functional scales or only 
symptoms scales, to form two additional outcomes focusing on each aspect. 
Patients with lower QoL and function or more disease symptoms were 
considered to have adverse outcomes. 
Patients were also asked to rate their own perception of fatigue on a 10 point 
scale (1-10). This measure of fatigue was used as diagnostic criteria and after 
visual inspection of the distribution and comparison with reference values for 
EORTC QLQ-C30 [132] a value >3 were used as cut-off (paper IV). 
 
Patients were classified as having cachexia using three recently published 
definitions; 1/ The 2- and 3-factor profile definitions described  by Fearon et 
al., incorporating WL (≥ 10%), low food intake (≤ 1500 kcal/day) and 
systemic inflammation (CRP ≥ 10 mg/L) (Fearon et al. 2006)[4]; 2/ The 
diagnostic criteria of Evans et al. with WL (> 5%) plus three of the 
following: decreased handgrip strength, fatigue, low EI, low muscle mass or 
abnormal biochemistry (CRP > 5 mg/L, anemia or low albumin) (Evans et al. 
2008) [3]; and 3/ The 2011 expert panel consensus definition of screening 
and staging of cachexia using WL, BMI or low muscle mass (Fearon et al. 
2011) [1]. 
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Group data are expressed as mean ± SD unless otherwise stated. Data were 
checked for normality with one-sample Kolmogorov-Smirnov test. When 
log-transformation restored normality the transformed data were used. Data 
were analyzed using SPSS for Windows version 11.5 (paper I) and 19.0.0 
(paper II-IV) (SPSS, Chicago, IL). A P-value < 0.05 was considered to be 
significant. 
Differences in proportions were analyzed with the χ2-test or Fisher‟s exact 
test, as appropriate. Differences between group means were tested with t-test 
for normally distributed data and with Mann-Whitney U-test for QoL data. 
Differences in means between more than two groups are assessed by 1-way 
ANOVA, and post hoc differences, by the method of Bonferroni. 
The association between ED and EI were analyzed with Pearson´s correlation 
coefficient and linear regression (paper I and II). Associations between 
mixed model estimated individual intercepts and slopes and subject 
characteristics were analyzed with Pearson‟s correlation coefficient (paper 
II). 
Linear mixed models were used to analyze the multi-level repeated measures 
data in paper II and III. In paper II, a mixed model was used to investigate 
the relationship between EI and ED and a number of patient characteristics. 
In paper III, the mixed model was used to investigate the relationships 
between energy balance and ED, EDfood, EI, systemic inflammation and 
survival. Details of the analyses are given below. 
Paper II 
Energy intake was the dependent variable. Fourteen explanatory variables 
were included from start: ED, age, sex, BMI, WL, tumor type, survival 
(tertiles), hypermetabolism, low serum albumin (<32 g/L), high CRP (CRP 
>5 mg/L), low ASMI (<7.25 in males and <5.45 in females), fatigue, 
handgrip strength (adjusted for sex and age) and day of dietary record. These 
variables were entered as fixed effects, which can be interpreted as estimates 
of group mean effects. Day of dietary record was entered as a repeated effect 
with a first-order auto-regressive covariance type and as a fixed covariate to 
model dependence and trend across days. Starting from the full model, the 
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explanatory variable having the highest p-value was excluded and the model 
was refitted in a stepwise backward selection procedure until all remaining 
explanatory variables in the model showed significance.  
Apart from the fixed effects, the model includes a random intercept and a 
random effect for ED. In a random intercept and slope model an intercept and 
slope is estimated for each individual in addition to the fixed effects. 
Significant random intercepts indicate that individual EI differs from the 
group estimate when accounting for explanatory variables in the fixed effects 
model. Similarly, significant random slopes indicate that individual responses 
in EI for a change in ED are different from the overall group response (fixed 
effect). 
ED was centralized by subtracting the population mean value from each 
observation. In this way the estimated variance of the random intercept can 
be interpreted as the between-subject variation in the mean response at the 
group mean value of ED. 
Paper III 
Energy balance was the dependent variable. The measurement period was 
entered as a repeated effect with a Toeplitz covariance type. If model 
convergence was not achieved, a first-order auto-regressive covariance was 
used. The last measurement period before death was considered to be 
common for all patients, in order to enable modeling of the natural disease 
progression. Thus, measurement periods were 0-4 (1
st
), 4-8 (2
nd
), 8-12 (3
rd
) 
and 12-16 (4
th
) months before the final follow-up appointment. ED and EI at 
the beginning of measurement periods were entered as continuous predictors. 
Additionally, models were adjusted at the beginning of each measurement 
period for (log transformed) survival in days, or by tertiles of survival. The 
presence of inflammation was defined by three criteria: the patient having an 
elevated level of CRP (two levels: CRP > 5, CRP > 10 mg/L) or having an 
ESR > 20 mm/h. The Glasgow Prognostic Score (GPS) was also used to 
define whether inflammation was present [43]. Schwarz's Bayesian criterion 
was used to select the inflammatory marker and measure of survival 
(continuous or tertile-based) that yielded the best model. Differences in 
patient characteristics and differences in dietary characteristics between 
patients with or without systemic inflammation were tested with a mixed 
model with repeated effects and test variable as the dependent variable. 
Cluster analyses were performed with K-means cluster analysis with a two 
cluster solution (paper IV). 
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Logistic regression was used to estimate the odds ratio of having low QoL, 
more symptoms or short walking distance with each diagnostic criteria or 
cachexia definition as a single dichotomized predictor (paper IV). 
Additionally, a stepwise forward logistic regression was fitted with all 
diagnostic criteria as possible predictors for an adverse outcome (paper IV). 
Survival analysis was conducted with a Cox proportional hazard regression 
model with each diagnostic criterion or cachexia definition as a single 
dichotomized predictor. A stepwise model with all predictors was also fitted 
(paper IV). Differences in survival (days) were tested with the log-rank test 
(paper IV). 
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The largest sample of patients were included in paper IV (n = 405) and these 
included nearly all of patients in the previous papers (Table 1). Thus, as an 
overview of patient characteristics and dietary intake of patients included in 
this thesis, data from paper IV is presented. 
 
Patient characteristics, WL, functional status and biochemistry of patients are 
shown in Table 3 and tumor types in Table 4. Patients had advanced disease 
with 54 % having distant metastases (stage IV), which is reflected in values 
for health status, functional status and a median survival of less than 6 
months (Table 3).  
Table 3. Patient characteristics at first visit (baseline) 
 n Mean ± SD Range 
Survival (days; median, IQR) 405 175 ± 235 1–6014 
Age (years) 405 68 ± 11 30–89 
BMI (kg/m2) 405 23.0 ± 3.8 15.7–38.4 
Weight (kg) 405 67.3 ± 13.8 35.4–119.7 
Weight loss (%) 405 10.0 ± 9.3 -16–45 
Hypermetabolism (%) 400 10.6 ± 13.1 -26–68 
CRP (mg/L) 399 32 ± 43 1–300 
ESR (mm/h) 375 39 ± 27 3–115 
S-Albumin (g/L) 398 34 ± 5 19–47 
Hemoglobin (g/L) 405 120 ± 16 67–165 
Fatigue (EORTC, 0-100) 331 52 ± 28 0–100 
KPS 290 84 ± 11 50–100 
Walking distance (m) Male 159 317 ± 214 34–1241 
 Female 145 242 ± 192 3–1400 
Abbreviations: CRP, C-reactive protein; EORTC, European Organization for Research and 
Treatment of Cancer Scale; ESR, Erythrocyte sedimentation rate; KPS, Karnofsky 
Performance Score. 
Weight loss was noted in 84 % of patients before study inclusion. Proportions 
of patients with WL more than 5, 10 and 15 % were 67, 46 and 27 % 
respectively. Patients also had low appendicular skeletal muscle mass (67 %) 
and the prevalence was higher in men (76 %, P < 0.001). 74 % had elevated 
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CRP (>5 mg/L) with some differences across tumor types (P = 0.02). 
Specifically, patients with upper gastrointestinal cancer had lower CRP than 
those with biliary tract cancer (P = 0.02). Patients with inflammation (CRP > 
5) had higher REE than predicted (12.1 vs. 5.8 % of BMR, respectively, P < 
0.001) and also experienced slightly more WL before inclusion (10.5 vs. 8.5 
%, respectively, P = 0.049). Fatigue (EORTC) was higher in patients with 
inflammation (median, 56 vs. 33, respectively, P = 0.001). Patients with 
pancreatic tumors had shorter survival than other tumor types (P = 0.04). 
Table 4. Tumor types 
Tumor type  n % 
Colorectal 91 22 
Biliary tract 59 15 
Upper gastrointestinal 107 26 
Pancreatic 105 26 
Other 43 11 
Total 405 100 
 
Energy intake ranged from 326 to 4715 kcal/day with mean intake of 
1762±639 kcal/day (n = 322) (Table 5). Expressed in relation to BW 
(kgBW), EI was 27.0±10.3 kcal/kg/day (range, 5.7–76.9 kcal/kg/day). Energy 
intake, expressed as a multiple of measured REE (EI/REE), ranged from 0.29 
to 2.87 with a mean of 1.18±0.41 (n = 318). 
Macronutrient intake, expressed as percent of total EI was 36 E% fat, 45 E% 
carbohydrate and 16 E% protein and thus did not differ from the general 
population in Gothenburg [133]. Dietary protein intake estimated from 24h 
urine nitrogen (n=53) according to Bingham and Cummings [134], were not 
significantly different from protein intake calculated from FRs (mean 
difference 4.5 ± 22.9 g/day, P = 0.15). Moreover, differences between 
estimates were not significantly different between sexes or by overweight 
status. However, there was a trend of FRs to overestimate protein intake at 
lower intakes and underestimate at higher intakes (r = -0.58, P < 0.001). 
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Table 5. Dietary intake 
 n = 322 Mean ± SD 
Energy intake (kcal) 1761 ± 639 
Energy intake(kcal/kg) 27.0 ± 10.3 
Energy intake (EI/REE) 1.18 ± 0.41 
Energy density (kcal/g) 0.90 ± 0.23 
Fat (g) 73 ± 34 
Carbohydrate (g) 201 ± 73 
Protein (g) 68 ± 25 
Protein (g/kg) 1.03 ±  0.4 
Alcohol (g) 3 ± 10 
Fiber (g) 13 ± 6 
Water (g) 1618 ± 674 
Food weight (g) 2042 ± 789 
Fat (E%) 36 ± 7 
Carbohydrate (E%) 45 ± 7 
Protein (E%) 16 ± 3 
Alcohol (E%) 1 ± 4 
Water (W%) 79 ± 8 
 
 
Energy density determined with the 4 different methods ranged from 0.88 ± 
0.23 to 1.67 ± 0.35 kcal/g. The lowest ED was measured with ED1 (nothing 
excluded) and rose with each successive method to ED4 (including solid food 
only). Means in ED determined with the different methods were significantly 
different from each other. 
The correlation between ED and EI was positive (r = 0.43, P < 0.001) and the 
association between ED and food weight was negative (-0.34, P < 0.001). In 
regression analysis ED explained 18, 15, 22 and 21 % of the variation in EI, 
for method 1 to 4 respectively (P for all < 0,001). In relation to energy per kg 
BW and REE, method 3 and 1, respectively, yielded the highest 
determination coefficient. Overall ED3 yielded the highest determination 
coefficient (Table 6). 
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Table 6. Determination coefficient (R2) in regression of different measures of 
energy intake (EI, EI/kg BW and EI/REE) and diet energy density, calculated 
with four different methods (Table 2). 
 Method   ED1   ED2   ED3   ED4 
Energy (kcal)         
R2  0.18  0.15  0.22  0.21 
Energy (kcal/kg)         
R2  0.16  0.10  0.16  0.16 
Energy (EI/REE)         
R2  0.18  0.16  0.18  0.15 
All regressions were significant, P < 0.001. 
Abbreviations: EI, Energy intake; R2, Determination coefficient; REE, resting energy 
expenditure. 
Age, BMI, fatigue and survival were negatively associated and 
hypermetabolism was positively associated with EI. Effect estimates (1 SD) 
were: -1.9 kcal/kg/d for age, -3.8 kcal/kg/d for BMI, -1.5 kcal/kg/d for fatigue 
and 1.1 kcal/kg/d for hypermetabolism.  For tertiles of survival, the effect 
was -4.3 kcal/kg/d for 1st and -2.6 kcal/kg/d for 2nd compared to 3rd. 
Patients with shortest survival (<3.7 months) had approximately 17 % lower 
EI than patients with more than 8.3 months survival. 
After adjustment with the above covariates, group mean estimate for ED (1 
kcal/g) were 17.5 kcal/kg/d (95% CI, 15.2-19.8) and expressed as 1 SD, 4.5 
kcal/kg (17.3 %) (P < 0.001) (Figure 1). When entering ED as the only 
predictor of EI in a mixed model with fixed, random and repeated effects, the 
group mean estimate for ED (1 kcal/g) was 18.5 kcal/kg/d (95%CI, 16.4-
20.6). Using linear regression with mean dietary ED predicting EI in these 
patients, the β-coefficient was 16.6 kcal/kg/d (95% CI, 11.9-21.3) (P < 
0.001), explaining 16.2% of the variation in EI.  With multiple linear 
regression with age, BMI, hypermetabolism, fatigue and tertiles of survival 
as covariates, the β-coefficient for ED was 13.6 kcal/kg/d (95% CI, 9,6-17.6) 
(p<0.001). Thus, estimates of the relationship between EI and ED from the 
mixed model and simple or multiple linear regression, with or without 
covariates were not significantly different judged by overlapping 95% 
confidence intervals. 
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Figure 1. Mixed model output estimating energy intake with selected patient 
characteristics (see text) and diet energy density (grand mean centered) as 
predictors. Overall (thick line) and individual (thin lines) estimated energy intake 
Day of dietary recording was negatively associated with EI in the mixed 
model (P < 0.02). Each successive day were associated with approximately 
1% lower EI. In addition, there was a repeated effect with covariance of EI 
between days (P < 0.001), indicating a positive dependence between days (r 
= 0.19, P = 0.003). 
Individual slopes (random effects) for ED were significant (P < 0.001), 
indicating that there was individual variation in the responses in EI for a 
change in ED that were different from the overall group response (fixed 
effect). Mixed model output illustrating the estimated individual variation in 
EI and the overall and individual EI:ED relationship is presented in Figure 1. 
Individual slopes for ED (subtracting group mean estimates) were negatively 
correlated with age and fatigue (r = -0.16 and -0.16, respectively, P < 0.013) 
and positively correlated with hypermetabolism (r = 0.16, P < 0.014) but not 
with any other patient characteristic. Individual slopes were positively 
correlated with EI, food intake (g) and beverage intake (g) (r = 0.30, 0.27 and 
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0.15 respectively, P < 0.02). There was also individual variation in EI that 
could not be accounted for in the present model as indicated by significant 
individual (random) intercepts (P < 0.001). Individual intercepts (i.e. EI) 
were negatively correlated with a high proportion of protein (E%) and fiber 
(W%) in the diet (r = -0.23 and -0.21, respectively, P < 0.001). EI were 
positively correlated with a high proportion of beverages (r = 0.28, P < 
0.001), both with and without energy (r = 0.18 and 0.16, respectively, P < 
0.013). 
 
Data from 107 patients who were followed through 164 periods was available 
to model four measurement periods over the 16 months before the final 
follow-up. An ESR value greater than 20 and tertiles of survival were the best 
predictors of energy balance, and these were consequently used in models to 
adjust for inflammatory status and survival. Missing data meant that 97 
patients who were followed through 145 periods remained in models adjusted 
for survival and inflammatory status. The mean energy balances were -126 ± 
250, -25 ± 237, 118 ± 239 and 85 ± 123 kcal/day for measurement periods 1 
to 4, respectively. 
In an unadjusted model, the EDfood and EI were positive predictors of energy 
balance (P < 0.03). A 1-SD increase in ED and EI increased energy balance 
by 38 and 41 kcal/day, respectively. The total diet ED did not predict energy 
balance (P > 0.05). Survival was positively (P < 0.001) and inflammatory 
status (measured as ESR > 20) was negatively (-98 kcal/day, P = 0.005) 
associated with energy balance over the following 4 months. The estimated 
energy balance for tertiles of survival from 1
st
 to 3
rd
 were -180 ± 31, -23 ± 30 
and 5 ± 23 kcal/day (mean ± SEM), respectively (Figure 2). Only EI 
remained a significant predictor of energy balance after adjustment for 
survival and inflammatory status. Patients with inflammation had a lower EI 
relative to BW (-9%, P = 0.04) while the EI was not significantly different (-
8%, P = 0.07). ED (-9%, P = 0.02) and EDfood (-8%, P = 0.01) were both 
significantly lower. There were no differences in macronutrient distribution 
(E%) or water intake between groups, but fiber intake was lower in patients 
with inflammation (-1.7 g/d, P = 0.04). 
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Figure 2. Energy balance per day estimated from change in body energy content by 
repeated dual-energy X-ray scans separated by 4 months, classified by tertiles of 
survival and inflammatory status (ESR > 20) 
 
Quality of life data were available for 331 patients. All cluster analyses 
created groups of patients with significantly different scores for all scales of 
the EORTC QLQ-C30 (P < 0.05). Forty three percent (43 %) of patients were 
in the adverse “QoL, function and symptom” cluster, 45 % in the adverse 
“QoL and function” cluster and 39 % in the adverse symptoms cluster. When 
comparing function scales of the “QoL and symptoms” clusters differences 
were largest for social function, global QoL and role function with effect 
sizes (ES) of -2.05, -1.86 and -1.44 respectively. Largest differences in 
symptoms were found for fatigue, pain and loss of appetite (ES 1.93, 1.53 
and 1.33 respectively). There were significant differences in survival, health 
status (WL, BMI, muscle indexes and biochemistry) and some measures of 
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physical function (grip strength in women and walking distance in men) but 
no difference in dietary intake between “QoL, function and symptom” 
clusters.  
Between clusters formed with only global QoL and function scales, the 
largest differences were found for social function, role function and global 
QoL (ES 2.12, 1.95 and 1.92 respectively), with differences in symptoms 
being less pronounced. Differences between the symptom clusters were 
largest for loss of appetite and fatigue (ES 2.39 and 1.71 respectively).  
Odds ratios for adverse QoL, function, symptoms and short walking distance, 
classified by different diagnostic criteria for cachexia are shown in Table 7. 
In the stepwise forward logistic regression model with all diagnostic criteria 
as possible predictors for an adverse outcome 162 patients were available for 
analysis. Low handgrip strength (lowest tertile), fatigue > 3 (10 point scale) 
and CRP>10 (mg/L) were associated with being in the adverse “QoL, 
function and symptoms” cluster (P < 0.05). The same three predictors with 
the addition of WL > 5% remained in the model with adverse “QoL and 
function” cluster as outcome (P < 0.05). Weight loss > 10%, fatigue > 3, 
protein intake < 1.2 (g/kg/day) and hemoglobin <120 (g/L) were significant 
predictors of being in the cluster with more symptoms (P < 0.02). In the 
stepwise model with walking distance less than average as outcome, fatigue > 
3 and ESR > 20 (mm/h) were associated with shorter walking distance (n = 
168, P < 0.001). 
There were 6 censored observations in the survival analyses. Hazard ratios 
from the Cox proportional hazards model with each diagnostic criterion as 
predictor and median survival for each classification are shown in Table 8. 
None of the dietary variables were significant predictors of survival (data not 
shown).  
In the stepwise Cox regression model with all diagnostic criteria as possible 
predictors for survival, 202 patients were available for analysis. Low 
handgrip strength, fatigue > 3 (1-10 scale), Karnofsky performance score <80 
and CRP>15 (mg/L) were prognostic of shorter survival (P < 0.03). 
Based on the results from the logistic and Cox regressions an alternative 3-
factor diagnostic criterion was constructed: WL >2%, Fatigue >3 (1-10 scale) 
and CRP > 10 mg/L (Table 7 and 8). 
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When excluding patients with less than 3 months survival, odds ratios for 
having an adverse outcome decreased for all cachexia definitions except for 
those of Fearon et al. 2006 [4]. In survival analysis only the 2 of 3 factor 
definition of  Fearon et al. 2006 [4] and our own alternative 3-factor 
definition remained significant predictors of  survival, with hazard ratios of 
1.4 and 1.6 respectively (P < 0.004). The prevalence of a diagnosis of 
cachexia decreased when excluding patients with less than 3 months survival; 
to 6 % (3-factor, Fearon et al. 2006), 38 % (2 of 3-factors, Fearon et al. 
2006), 28 % (Evans et al. 2008), 82 % (Fearon et al. 2011) and 26 % (our 3-
factor alternative), respectively.  
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Table 7. Odds ratio for adverse QoL, function, symptoms and walking 
distance in patients with advanced cancer (n = 405), classified by different 
diagnostic criteria for cachexia. 
 Odds ratio for adverse outcomea 
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BMI < 20 2,9 2,7 2,6  21 0 
BMI < 20 and weight loss > 2% 2,8 2,6 2,5  20 0 
Weight loss > 2% 2,1 2,1 1,9  77 0 
Weight loss > 5% 1,7 1,8 2,0  67 0 
Weight loss > 10% 1,8 1,9 1,9  46 0 
Walking distance less than average 2,3 2,2 3,3 - 58 25 
Handgrip strength in lowest tertile 2,5 2,3 2,2 2,7 35 31 
Fatigue < 3 (1 to 10 scale) 4,0 4,5 4,0 3,3 63 28 
Karnofsky performance Score < 80 3,4 2,7 3,6  17 28 
EI < 20 (kcal/kg/day)     28 21 
EI < 1500 (kcal/day)   2,3 2,0 39 21 
EI less than average (1756 kcal/day) 1,9  3,1  53 21 
Protein intake < 1.2 (g/kg)   2,0  69 21 
ED less than average     49 21 
Low AMC 2,3 1,9 2,1  15 1 
Low ASMI 2,0 2,1 1,8 2,0 67 4 
Low muscle mass 1,8 2,0  2,0 66 0 
CRP > 5 (mg/L) 2,1 2,3 2,6 3,9 74 2 
CRP > 10 (mg/L) 3,1 3,6 2,4 3,6 59 2 
CRP > 15 (mg/L) 3,0 3,0 2,4 3,1 49 2 
ESR > 20 (mm/h) 1,7 2,0 1,7 4,2 70 7 
ESR > 30 (mm/h) 1,7 1,7 1,6 3,2 50 7 
S-Albumin < 32 (g/L) 1,9 2,2 1,7 3,2 30 2 
Hemoglobin < 120 (g/L) 1,7 1,6 2,1 1,9 48 0 
Cachexia all 3 factors (Fearon 2006) 5,3 4,4 5,1 3,5 12 22 
Cachexia 2 of 3 factors (Fearon 2006) 2,1 2,6 2,6 2,1 45 22 
Cachexia (Evans 2008) 2,3 2,3 3,1 3,1 33 33 
Cachexia (Fearon 2011) 2,6 3,4 2,2  85 0 
Cachexia (WL>2%, Fatigue>3, CRP>10) 2,5 3,2 2,6 4,2 37 30 
aOnly statistically significant odds ratios are shown (P < 0.05).  
Abbreviations: AMC, mid-arm muscle circumference; ASMI, appendicular muscle mass index; CRP, C-
reactive protein; ED, diet energy density; EI, energy intake; ESR, Erythrocyte sedimentation rate; WL, 
weight loss. 
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Table 8. Table 4. Survival analysis with Cox-proportional hazards model in 
patients with advanced cancer (n = 405), classified by different diagnostic 
criteria for cachexia. 
  Median survival (days) 
  Diagnostic criteria  
 Diagnostic criteria Hazard ratioa Negative Positive Difference  
     
BMI < 20     
BMI < 20 and weight loss > 2%     
Weight loss > 2% 1,4 251 146 -105 
Weight loss > 5% 1,3 243 147 -96 
Weight loss > 10% 1,2 203 133 -70 
Walking distance less than average 1,3 240 146 -94 
Handgrip strength in lowest tertile     
Fatigue < 3 (1 to 10 scale) 1,6 249 131 -118 
Karnofsky performance Score < 80 1,5 182 101 -81 
Low AMC 1,3 183 128 -55 
Low ASMI     
Low muscle mass     
CRP > 5 mg/L 1,8 290 138 -152 
CRP > 10 mg/L 2,2 291 120 -171 
CRP > 15 mg/L 2,3 255 110 -145 
ESR > 20 1,6 257 149 -108 
ESR > 30 1,7 241 135 -106 
S-Albumin < 32g/L 2,0 224 107 -117 
Hb < 120g/L 1,4 236 135 -101 
     
Adverse QoL and Symptoms 1,6 249 120 -129 
Adverse QoL 1,6 253 126 -127 
More Symptoms 1,6 244 120 -124 
     
Cachexia all 3 factors (Fearon 2006) 2,2 202 85 -117 
Cachexia 2 of 3 factors (Fearon 2006) 1,7 252 126 -126 
Cachexia (Evans 2008) 1,4 197 115 -82 
Cachexia (Fearon 2011) 1,3 249 157 -92 
Cachexia (WL>2%, Fatigue>3, CRP>10) 2,1 240 91 -149 
  
 
    
 aOnly statistically significant hazard ratios are shown (P < 0.05). 
Abbreviations: AMC, mid-arm muscle circumference; ASMI, appendicular muscle mass 
index; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; QoL, quality of life; 
WL, weight loss. 
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The present studies are the first attempt to examine dietary ED and its 
relation to EI in cancer patients using both a between- and within-subject 
analysis. Energy density of the diet was associated with EI in all analyses. 
Paper III is the first examination of EI and dietary ED and their relationships 
with energy balance in cancer patients. As expected, EI was positively 
associated with energy balance; however, only EDfood was associated with 
energy balance. These results support current dietary practice recommending 
an energy-dense diet to cachectic cancer patients. 
When we applied several popularly used criteria for cancer cachexia we 
found that WL, fatigue and markers of systemic inflammation were most 
strongly and consistently associated with adverse QoL, reduced functional 
abilities, more symptoms and shorter survival, which support that these are 
among the key features that should be assessed to characterize a patient with 
cachexia. 
 
Patients included in this thesis were an unselected and heterogeneous group 
of cancer patients referred to a palliative care program. A majority of patients 
had gastrointestinal cancers (89%). Accordingly, the results may not be 
representative or generalizable to other groups of cancer patients, who may 
have a different etiology of anorexia and cachexia. We found differences in 
CRP and survival among tumor types. In the mixed models, both survival and 
signs of inflammation were used as covariates which would adjust for 
differences among tumor types. In paper II we entered tumor type as a 
covariate and it was not significant. 
Interventions included anti-inflammatory treatment with indomethacin, of 
anemia with erythropoietin, insulin, dietary counseling and nutritional 
support [20-23]. The effects of concomitant anti-inflammatory treatment 
should consequently be considered when evaluating our results. More than 
90% of patients were being treated with indomethacin in the analysis of 
energy balance (paper III). Therefore we chose to adjust for signs of 
inflammation per se, rather than its treatment to assess the effects of 
inflammation. However, we cannot infer that dietary diaries precisely reflect 
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the actual eating behavior of advanced cancer patients without anti-
inflammatory treatment or that there are no differences in eating behavior 
between patients with different tumor types. Results in the longitudinal 
follow-ups do not reflect alterations during disease progression that were 
fully spontaneous: they present an integrative view over time, according to 
the evidenced-based treatment offered. 
In the intervention studies emphasis in dietary intake was on energy and 
macronutrients [20-23]. Consequently, when FRs were returned and checked 
for incomplete recordings energy-free beverages were not specifically asked 
for, which may have increased underreporting. Underreporting of energy-free 
beverages between days or between patients will affect the calculated ED and 
consequently the estimated relationship between ED of the total diet and EI. 
Inclusion of energy free-beverages when calculating ED would be expected 
to decrease the association between ED and EI if under reporting were 
substantial. In contrast, the inclusion of energy free beverages increased the 
association between ED and EI (comparing ED1 to ED2, table 6) and 
consequently does not support that there were substantial under reporting of 
energy free beverages. Energy and water intake varied widely between 
subjects; however, it is not possible to classify patients as under or over 
reporters using cut-off values from healthy populations in this sample of 
unselected palliative care cancer patients with ongoing WL. An alternative 
approach was used in paper II where patients were excluded if EIs were 
outside of ±3SD. 
Energy intake in relation to BW decreased with increasing BMI in the present 
study. This could be due to underreporting in people with higher BMI‟s, 
assuming that physical activity levels were the same across the BMI range. 
This is a common phenomenon in dietary surveys [135], but one we didn‟t 
expect to find in this population of weight losing cancer patients. Analysis of 
urinary nitrogen did not indicate underreporting of protein intake in a sub 
sample of our patients but there could still be underreporting of non-protein 
rich foods. Dietary protein intake estimated from urine nitrogen were on the 
contrary 4.5 g/day lower (P = 0.15) than estimated intake from FRs even 
after accounting for incomplete collection of urine according to the method of 
Bingham and Cummings [134]. Estimates were also not significantly 
different stratifying by overweight status. However, there was a trend of FRs 
to overestimate protein intake at lower intakes and underestimate at higher 
intakes (r = -0.58, P < 0.001) which may support that there were systematic 
over- and underreporting at low and high BMI‟s respectively. Since urine 
was only collected for only 24h during the 4-days of FR this correlation 
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could arise by regression to the mean, which would be expected to some 
degree. The limited number of patients with urine collections prevents any 
definite conclusions regarding urinary nitrogen and dietary reporting. 
The association with decreasing EI with higher BMI‟s may also be due to 
high EI in patients with low BMI attempting to counteract WL. In a 
systematic review Blum et al. found that reported EI related unreliably to WL 
which, given our results, to some degree could be due to confounding by 
BMI [5]. Yet another explanation may be that subjects with higher BMI have 
a higher proportion of adipose tissue to lean body mass and thus lower 
energy expenditure per kg [136]. BMI or body composition may therefore be 
important covariates to consider when assessing dietary adequacy from 
dietary records also in patients with advanced cancer. 
It is inherently difficult to study the association between two variables when 
they are mathematically related, as in the case of EI and ED (i.e. kcal and 
kcal/g). The variables X and X/Y will be correlated even if X and Y are 
random numbers. Consequently, diet ED and EI are expected to be 
correlated. However, in the presence of human EI regulation, EI and ED 
would not be correlated if any change in diet ED were precisely compensated 
by a reciprocal change in amount of food eaten to reach a specific EI. This 
would constitute perfect EI regulation. On the other hand, if people would eat 
the same amount of food (by weight) every day, then EI would be precisely 
dependent on diet ED and the two would be perfectly correlated with no 
apparent EI regulation. It is also possible, however, that humans choose more 
energy-dense foods when energy demands increase or vice versa, although 
evidence for this is largely lacking [137-139]. In that case ED will be 
correlated with EI even in the presence of perfect EI regulation. 
Any correlation between EI and ED in these scenarios would thus represent 
the uncompensated or “true” relation between EI and ED and any 
measurement error in either variable would obscure this relationship. 
However, the direction of causality cannot be established. 
The cross-sectional design, the short period of dietary recording in the 
analysis of day-to-day variation and a possible impact of dietary misreporting 
limit the conclusions that can be drawn. Increased number of days of dietary 
recording would be preferable but are in our opinion not feasible in this 
patient group.  
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Strengths include the use of a multivariate mixed linear model, which 
correctly models non-independent hierarchical data with repeated measures, 
in a large sample of patients with advanced cancer. This allowed for a better 
estimate of the impact of diet ED on EI while accounting for between subject 
differences. 
The inclusion of exercise and non-exercise energy expenditure (apart from 
REE) in the models might explain part of the unexplained variance in EI and 
energy balance. Since these variables were not measured, this precludes us 
from making any conclusions of their impact on these relationships. 
Strengths also include the high precision with which energy balance was 
measured and the longitudinal follow-up. However, the reliability of 
estimates of the impact of ED and EI on energy balance are limited by 
imprecision in the measure of food intake and by the low number of patients 
in that analysis. The requirement for several body composition measurements 
separated by 4 months limited the number of patients from the cohort that 
could be included in the analysis. 
Strengths in the analysis of different diagnostic criteria and adverse outcomes 
include the large number of diagnostic variables measured with appropriate 
methods simultaneously in a relatively large sample of patients with 
advanced cancer. The use of cluster analysis that clearly separated patients 
with adverse QoL, function and symptoms may also be considered a strength 
of this analysis. 
Limitations include the number of missing values in some of the variables, 
which reduced the number of patients available for multi-factor and 
multivariate analysis. Missing measures is a reality in care of patients with 
advanced cancer, diagnostic measures should therefore be accessible and 
easy to perform in routine care [1].  
 
Where methods of ED calculation are comparable, the observed dietary ED 
in this study is close to the observed ED in larger community studies in the 
U.S. and Spain in healthy populations of similar age, so it appears that the 
diet ED in this group of cancer patients does not differ much from what has 
been observed in healthy populations [16, 17, 140]. 
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Dietary energy density was associated with EI regardless of calculation 
method and both in a between- and within-person analysis. The ED of food 
predicted energy balance, but the association was not significant when 
systemic inflammation was considered. Overall, the results were in 
accordance with findings in elderly, healthy and overweight free-living 
people in both experimental and observational studies [15-17, 19, 87, 89-92, 
141]. 
The results from paper I indicated that the method used when calculating ED 
had little impact on the association between ED and different measures of EI 
(absolute, per kgBW and EI/REE). In relation to absolute EI and per kg BW 
the exclusion of all beverages except milk (ED3) gave the highest 
determination coefficient (R
2
) and overall ED3 seemed to be the best measure 
(Table 6). It is interesting that the inclusion of non-energy containing 
beverages increases the association between ED and EI compared to ED 
calculated including energy containing beverages only (ED2); this in part 
contradicts earlier research on healthy subjects that non-energy beverages 
does not influence EI [19, 97, 99, 142]. This could indicate that in cancer 
patients with limited dietary intake, the total volume of food and drinks is a 
limiting factor in respect to EI. Stomach filling has indeed been suggested to 
partially mediate the influence of ED on food intake even in healthy subjects 
[143]. In the mixed model energy free beverages were positively correlated 
with EI which would seem contradictory. However, the positive association 
could arise if patients with a limited food intake reduced their intake of 
beverages, supposedly to reduce food volume. Alternatively, patients with 
low intakes may underreport their beverage intake. 
In our longitudinal analysis, ED of solid food (including milk) was positively 
associated with long-term energy balance in an unadjusted model. This 
association persisted; indeed it increased, after adjustment for survival. In 
contrast, total ED of the diet were not associated with energy balance in any 
model. This suggests that it is EDfood that affects EI and ultimately energy 
balance in cancer patients with limited food intake. This result agrees with 
those of studies in healthy subjects, where EDfood is associated with long-term 
energy balance and the association depend on whether water and less 
energy-dense drinks are included in the calculation [87]. Accordingly, the 
effect of the ED of food and energy from beverages should be separated in 
future analyses. 
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Our results imply that diet ED and in particular EDfood affects EI and energy 
balance to some degree, which supports current dietary practice. If there is no 
compensatory change in the amount of food, then an ED that is 1 SD higher 
(an increase of approximately 16-25%) would correspond to an increase in EI 
of approximately 350-450 kcal. Some compensation is, however, expected. 
ED was negatively associated with the amount of food ingested (food weight) 
which indicate EI compensation. The effect of increased ED would thus be 
compensated for by a smaller portion size or reduced meal frequency. 
Consequently, an increase in EDfood of 1 SD was correlated in this patient 
group with an increase in EI of approximately 190 kcal (10%). A 
compensatory change in total energy expenditure may be expected in cancer 
patients during semi-starvation, mainly due to changes in the level of 
physical activity [36]. Consequently, only a minor part of a change in EI is 
reflected in the energy balance. Our results, showing that an increase in ED 
of 1 SD is associated with an increase in energy balance of approximately 40-
50 kcal/day, support this. 
Average daily EI decreased during days of dietary recording. This could be 
an effect of dietary recording in itself (wear-out effect) or an initial effort to 
increase dietary intake that could not be upheld across the recording period, 
i.e. EI compensation between days, albeit at low levels of EI. The repeated 
measures covariance indicates dependence between days which could be due 
to EI regulation but the positive correlation indicates clustering of high or 
low EI, possibly due to disease symptoms, environmental or social 
circumstances [63, 144]. In healthy subjects de Castro reported a 2 to 3 day 
lag in EI compensation [145]. If the same applies to our patient sample our 
results would indicate EI regulation between days to some degree. 
Lowering the water content of food while increasing the fat content is the 
most effective way of increasing dietary ED. Increasing the ED by 25% 
would require a decrease in water content of ~5% and an increase in fat 
content of ~10 E%. For example, substituting boiled potatoes for pan-fried 
potatoes would increase the ED by 43%, and substituting natural yoghurt 
with 3% fat for yoghurt sweetened by sugar and having a fat content of 7% 
would increase the ED by 215%. Thus, exchanging several foods and 
beverages for corresponding energy-dense options could increase diet ED 
substantially. 
Diets rich in protein (E%) and fiber (W%) were associated with lower EIs 
even after accounting for their influence on ED. This could possibly be 
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explained by the higher satiating properties of protein and fiber, which have 
been documented in healthy and obese [146, 147] and may consequently also 
apply to cancer patients. Recommending less energy-dense fiber rich foods to 
weight losing patients is counterintuitive and our results also support this. 
The importance of an adequate protein intake in disease related malnutrition 
is well established and high-protein supplements have been shown to produce 
clinical benefits, including increased EI and weight gain [103]. High-protein 
diets should therefore be recommended despite that such diets supposedly are 
more satiating. Rather, different protein sources should be explored for their 
anabolic, anti-catabolic and satiating properties to optimize their effect in 
different disease states [148, 149]. 
The inclusion of between-subject covariates did not substantially impact the 
positive association between EI and ED. This implies that diet ED is likely to 
be an important factor when attempts are made to increase EI in 
malnourished cancer patients with a limited capacity of food intake, similarly 
to what has been found in elderly [89-91]. 
In this group of cancer patients there were individual variations in the 
responses in EI for a change in ED that were different from the overall group 
response. Specifically, age and fatigue were associated with lower EI and 
with flatter ED:EI slopes. There was also a positive association between EI 
and individual ED:EI slopes, which means that patients with low EIs have 
flatter ED:EI slopes. This implies that some patients could be less likely to 
respond favorably to an increase in diet ED, particularly the elderly and 
fatigued with low EI. 
 
The association between ED of food and energy balance was not significant 
when systemic inflammation was considered. Patients with an ESR > 20 had 
lower dietary ED, EI and fiber intake than other patients, while the amount of 
food and degree of hypermetabolism were similar. While causality cannot be 
inferred, the results imply that ingestive behavior and choice of food change 
in the presence of systemic inflammation, which leads to a lower EI and 
negative energy balance. However, systemic inflammation (CRP > 5 mg/L) 
was not significant in the mixed model predicting EI and were also not 
correlated with the individual EI:ED slopes. This could partly be explained 
by the possible impact of inflammation on fatigue and hypermetabolism and 
their association with EI, explaining more of the variance in EI than the 
dichotomized marker of inflammation alone. More importantly regarding the 
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association between EI and ED is the fact that individual EI:ED slopes were 
not associated with systemic inflammation. Thus, while EI and ED may be 
low in patients with inflammation the positive association between EI and 
ED may still be the same as in patients without.  
Energy balance became more negative during the final 5 months of life, and 
patients with inflammation differed from those without, especially in patients 
with longer survival (2
nd
 and 3
rd
 tertiles) (Figure 1). Our results thus highlight 
the importance of targeting systemic inflammation in the prevention and 
treatment of cancer cachexia with nutrition support [22, 31, 43, 53, 150]. 
The most common measure of systemic inflammation in cancer patients has 
been the level of CRP. Interestingly, we found ESR > 20 to be the 
inflammatory marker that was most closely associated with energy balance. 
ESR may reflect more accurately a long-standing inflammatory state, while 
CRP is more sensitive to acute changes, such as incidental infection. 
However, CRP with a cut-off of 10 mg/L seemed to be the best predictor of 
adverse QoL, symptoms and shorter survival, although differences between 
the cut-off levels were small. Our results support that serum CRP level is a 
useful marker of systemic inflammation and a key feature of cancer cachexia 
[1]. However, both markers, at different cut-off levels, reflect essentially the 
same influence on the associations studied, and the limited number of 
patients precludes further conclusions. 
 
Weight loss, fatigue and markers of systemic inflammation were the criteria 
for cancer cachexia that were most strongly and consistently associated with 
adverse QoL, reduced functional abilities, more symptoms and shorter 
survival. All cachexia definitions used were associated with adverse 
outcomes and prognostic of survival. 
The use of cluster analysis to separate patients with adverse QoL, function 
and symptoms worked well and large clinically meaningful differences were 
found in most scales of the EORTC QLQ-C30 [151]. Between the “QoL, 
function and symptoms” clusters the largest differences were found in global 
QoL and all function scales, but also in pain, fatigue and appetite. Similarly, 
the symptom only clusters weighed heavily on loss of appetite and fatigue, 
which suggests that the two are related. In agreement with a meta-analysis of 
studies using the EORTC QLQ-C30 all of the clusters with adverse outcomes 
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were associated with shorter survival [64]. Our results support that patient-
reported functional and psychosocial effects and symptoms are among the 
key features that should be assessed to characterize a patient with cachexia 
[1]. 
Weight loss of any degree was associated with both adverse QoL and shorter 
survival and might be a better reflection of an ongoing process of negative 
energy balance and progressive disease than BMI in this population. This 
agrees with most previous studies showing WL to be a significant prognostic 
variable for survival in advanced cancer [33]. 
Patients with shorter survival had substantially lower EIs and increasingly 
negative energy balance. This could be expected and fits well to the 
suggested classifications and stages of cancer cachexia (Figure 2) [1, 4]. 
Energy intake as a dichotomized predictor was not associated with survival 
and was not consistently associated with adverse outcomes other than more 
disease symptoms. Diet ED was not associated with any outcome. Reduced 
food intake is undoubtedly one of the main features of cachexia and should 
be assessed routinely [1]. In our study however, the dietary assessment with 
the classification criteria used seemed to be of little prognostic value. Rather 
the symptom scales of the EORTC QLQ-C30 that capture some of the 
underlying causes of reduced food intake, such as loss of appetite, nausea, 
diarrhea, constipation and fatigue appeared to be of better prognostic value. 
These results question the validity of using FRs as a diagnostic criterion. In 
paper III on the other hand, EI as a continuous predictor was associated with 
long term energy balance which shows that a 4-day FR has some predictive 
validity of EI over the following 4 months. For energy intake to be predictive 
of adverse outcomes it may be more appropriate to evaluate EI compared to 
estimated expenditure on an individual basis. This is a challenging task that 
may not be possible as a screening activity or in use as a diagnostic criterion. 
Fearon et al. suggests in their consensus findings that the patient‟s own 
estimate of overall food intake in relation to normal may be used to assess 
food intake [1] which, given our results, seems like a more appropriate 
option. 
The prevalence of a diagnosis of cancer cachexia varied widely according to 
the definition used (Table 3). In one end of the spectrum was the 3-factor 
definition of Fearon et al. [28] with prevalence of 12 % and in the other the 
consensus definition of Fearon et al. [1] with prevalence of 85 %. The former 
included patients with more advanced cachexia which was strongly 
associated with adverse QoL, symptoms and a median survival of less than 3 
months and as such may already entered a state of refractory cachexia. The 
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more inclusive consensus definition [1] was also associated with adverse 
QoL and symptoms but not with a shorter walking distance. In these patients 
with less of a functional decline and a longer survival, anti-cachectic 
treatment may be timely and efficient. Main determinants for a cachexia 
diagnosis according to the consensus definition [1] were the high prevalence 
of WL > 5% (67 %) and low muscle mass (66%) together with WL > 2% (77 
%), while BMI < 20 contributed marginally (Table 8). 
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We found a positive association between diet ED and EI in palliative care 
cancer patients. 
Age, BMI, fatigue, survival and hypermetabolism are associated with EI, but 
do not substantially influence the association between ED and EI. However, 
individual variation in response implies that some patients could be less 
likely to respond positively to an increase in dietary ED, particularly the 
elderly and fatigued with low EI. 
The energy intake and ED of the food consumed are associated with energy 
balance in patients with advanced cancer. This conclusion justifies current 
dietary practice and encourages future dietary interventions. Our results 
suggest also that the associations of EI and ED with energy balance are 
influenced by systemic inflammation. Thus, targeting systemic inflammation 
may be important in nutritional interventions in this patient group. 
ED of solid food (including milk) was positively associated with long-term 
energy balance. In contrast, total ED of the diet were not associated with 
energy balance. This suggests that it is EDfood that affects EI and ultimately 
energy balance in cancer patients with limited food intake. Accordingly, the 
effect of the ED of food and energy from beverages should be separated in 
future analyses. 
Weight loss, fatigue and markers of systemic inflammation were the criteria 
for cancer cachexia that were most strongly and consistently associated with 
adverse QoL, reduced functional abilities, more symptoms and shorter 
survival. All the cachexia definitions used were associated with adverse 
outcomes and prognostic of survival, but the prevalence of cachexia using 
criteria of the different definitions varied widely; especially in patients with 
more than three months survival – from 6 to 82 per cent – indicating a need 
to further explore and validate diagnostic criteria for cancer cachexia. 
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Additional studies are required to understand the impact of energy-dense 
diets in cancer patients on both EI and energy balance. The impact of diet ED 
should be confirmed in additional longitudinal follow-ups or preferably in 
dietary interventions. In future studies, the effect and degree of compensation 
in dietary intake when dietary characteristics that influence ED change 
should be monitored. Such studies should also pay attention to the effects of 
ED in solid food as well as the impact of energy containing and energy free 
beverages. In addition, possible subject characteristics (age, BMI, physical 
activity level, inflammatory status, stage of disease and cachexia) and 
nutrition impact symptoms (fatigue, appetite loss, pain and gastrointestinal 
symptoms) that may influence this relationship should be considered. 
To further explore and validate different diagnostic criteria in the diagnosis of 
cancer cachexia we suggest for future research that several different cut-off 
values be used for the main features of cachexia, similarly to the approach in 
this thesis. The diagnostic criteria and classification of the cachexia stages 
need further validation to better select patients with high enough sensitivity 
and specificity for interventions that are clinically relevant and tailored for 
the specific stages: precachexia, cachexia and refractory cachexia [1, 2]. 
Generally applicable diagnostic criteria would be valuable but clearly there 
are populations that may need specific modification. Definite cut-offs for the 
criteria that relate optimally to patient centered outcomes could be developed 
from large contemporary datasets [1]. 
Cancer cachexia is by definition a multifactorial syndrome and as such 
requires a solution that is multidimensional. It is self-evident that optimal 
oncological management must be achieved to get the best response of anti-
cachexia therapy. The development of cachexia is complex and involves a 
number of partly interrelated factors. Therefore, the best supportive care for 
cancer cachexia remains unresolved. Any single therapy is unlikely to be 
fully successful and combination therapies are at present the most logical and 
promising solution [1, 9, 10, 26, 37]. 
There are principally two main domains of cachexia therapy; reduced food 
intake and metabolic disturbances [8-10, 37]. Nutrition support, including 
dietary counseling, ONS and artificial nutrition as appropriate, possibly 
together with appetite stimulants will support nutritional intake [11, 20, 60-
62, 68]. Optimal management of nutrition impact symptoms is also key 
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factors that need to be addressed to support food intake and also improve 
QoL[26, 63]. 
Anti-inflammatory treatment to modify the host-tumor response together with 
anabolic and anti-catabolic therapies can reduce the metabolic disturbances 
and possibly restore the impaired appetite and anabolic response to nutrition 
and exercise [8, 10, 37, 45, 51, 60]. Anemia therapy and exercise could 
further improve fatigue and physical activity [73, 152]. These combination 
therapies could thus result in improvement of important patient centered 
outcomes such as physical activity, function, QoL and survival. It is clear 
however that further study is needed to determine the most effective mode of 
treatment. 
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